Controlling alpha in a clinical trial: t
โ
Ralph B. D'Agostino Sr
๐
Article
๐
2000
๐
John Wiley and Sons
๐
English
โ 44 KB
๐ 2 views
We have become masters of clinical trials. We design them beautifully, our protocols delineate objectives and categorize sharply e$cacy variables as primary or secondary, teams of investigators execute them e$ciently and then we analyse with the latest and most sophisticated statistical methods. Yet